甘露聚糖肽治疗原发性白细胞减少症的临床观察

Clinical Observation of Mannatide in the Treatment of Primary Leukopenia

目的：探讨甘露聚糖肽治疗原发性白细胞减少症的临床疗效和对患者机体免疫功能的影响。方法：2009年1月-2012年10月原发性白细胞减少症患者80例,按照随机数字表法随机分为治疗组和对照组,各40例,对照组服用地榆升白片,治疗组服用甘露聚糖肽胶囊,4周1个疗程,共2个疗程。结果：治疗组临床有效率为92.50%,明显优于对照组的75.00%（P〈0.05）。治疗组起效较快,用药6-9天就见患者临床症状明显改善,而对照组需要15-22天。治疗结束时治疗组患者T淋巴细胞亚群CD3＋、CD4＋、CD4＋/CD8＋也明显高于对照组（P〈0.05）。结论：甘露聚糖肽能改善原发性白细胞减少症患者免疫功能,升高外周血白细胞总数。

Objective：To investigate the clinical efficacy of Mannatide in the treatment of primary leukopenia and its impact on the immune function of patients.Methods：80 patients with primary leukopenia admitted to the hospital from January 2009 to October 2012 were randomly divided into treatment group and control group according to the random number table.40 patients in the control group received Diyushengbai tablets,patients in the treatment group were given Mannatide tablets for a course of four weeks,a total of two courses.Results：The effective rate of treatment group was 92.50%,which was significantly better than 75.00%of the control group （P〈0.05）. The treatment group had rapid effect,only took 6-9 days to see significant improvement in clinical symptoms,while the control group took 15 to 22 days.Tlymphocyte subsets CD3＋, CD4＋, CD4＋/CD8＋were also significantly higher （P〈0.05） than the control group at the end of treatment.Conclusion：Mannatide can improve immune function in patients with primary leukopenia and elevate peripheral blood leukocytes.